Semaglutide is a GLP-1 receptor agonist that works by: Reducing appetite Increasing fullness Slowing gastric emptying Improving insulin sensitivity Brand-name versions include: Ozempic (commonly used off-label for weight loss) Wegovy (FDA-approved specifically for chronic weight management) Semaglutide has one of the largest bodies of clinical evidence in obesity medicine
Results May Vary Individual results will vary based on factors including age, baseline weight, metabolic health, consistency of medication use, lifestyle factors (diet, physical activity, sleep), genetic factors, current medications, and other individual variables
Signals quantified by densitometry were normalized to -actin
Geniposide, acting as a GLP-1R agonist, partially prevented STZ-induced learning and memory impairment via modulation of PI3K/GSK-3 signaling pathway and reduced STZ-induced hyperphosphorylation of tau protein (220)